ClinicalTrials.gg
RecruitingNCT05329350mVSD RegistryUpdated Jul 30, 2026

Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases

An observational study in Muscular Ventricular Septal Defect, sponsored by Occlutech International AB. Recruiting at 6 sites in 3 countries. Open to participants aged 3 Months to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Occlutech International AB · Observational

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
3 Months to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Heart Defects, Congenital with a site in Turkey — 11 open to participants now, 12 under way, none of them phase 3. Heart Defects, Congenital · Turkey.

Planned enrollment
10th of 14
50 · median 71
Started
2022
with 5 others
Observational
14 of 32
3 open now
Primary completion
2031-01
later than 11 of 11 live
Registered
4th of 32
by date

Among the 32 studies in Heart Defects, Congenital with a site in Turkey, this one is the 10th largest by planned enrollment of the 14 observational ones that give a count, is one of 6 that started in 2022, is one of 14 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 4th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

11 of the 32 studies in Heart Defects, Congenital with a site in Turkey are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 3 Months to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Heart Defects, Congenital with a site in Turkey, or all of them as a file.
02

Study summary

The Occlutech® mVSD is indicated for percutaneous occlusion of hemodynamically or clinically significant muscular ventricular septal defects.

The objectives of the study are:

  • To confirm the efficacy of Occlutech mVSD in patients requiring transcatheter occlusion (closure) of muscular ventricular septal defects.
  • To confirm the safety of Occlutech mVSD in patients requiring transcatheter occlusion (closure) of muscular ventricular septal defects.
Read the detailed description

This is a multicenter, prospective, and retrospective, international, post-market clinical follow-up Study to monitor the efficacy and safety of the Occlutech mVSD in patients with muscular ventricular septal defects.

Safety and efficacy of implanted devices are assessed by echocardiography, vital signs, laboratory tests, and ECGs on Day 1 (within 48 hours post-procedure), follow-up 1 (between Day 30 and Day 60), follow-up 2 at 6 months (from Day 61 until 6 months), follow-up 3 at 1 year (from 6 months until 1 year), and follow-up 4 at 3 years (from 1 year until 3 years).

  • Patients will be screened to determine eligibility for the registry based on inclusion/exclusion criteria, through their medical history, demographics, vital signs, clinical laboratory tests, performance of a 12 lead electrocardiogram (ECG) and echocardiography data.
  • Participants are treated according to the instructions-for-use (IFU) of the device and according to clinical routine.
  • Procedures are performed at sites having appropriate laboratory support and adequately trained imaging personnel. The procedure is performed by physicians with experience in a wide range of interventional cardiology and structural heart disease, including transcatheter patent ductus arteriosus, atrial septal defect, and ventricular septal defect (VSD) closures.

Recruitment will be open until 50 Patients have been enrolled. The primary safety endpoint is defined as the incidence of Serious Adverse Device Effects (SADEs) including procedure-related death, procedure-related stroke, ischemic stroke, systemic embolism, severe hemolysis, complete heart block requiring pacemaker implantation or device explanation, new onset of severe tricuspid regurgitation (TR), new the onset of severe aortic regurgitation (AR), severe right-left ventricular outflow obstruction (RVOTO-LVOTO), device embolization, cardiac tamponade, infective endocarditis, or vascular complications requiring open heart surgery up to 1 year after the mVSD closure procedure.

The primary efficacy endpoints will include data obtained 1 year after the mVSD closure procedure for successful implantation of the device with a proper closure of the mVSD (defined as the reduction in muscular ventricular septal shunt to trivial or no shunt at all, as assessed by echocardiography pre- vs post-implantation).

03

Conditions studied

  • Muscular Ventricular Septal Defect

Keywords

  • mVSD Occluder
  • mVSD
  • Occlutech
  • Occlutech mVSD Occluder
  • Muscular ventricular septal defect closure
  • Transcatheter closure
  • Percutaneous occlusion
  • Periventricular closure
  • Post-market clinical follow-up
  • PMCF
  • Congenital heart defect
  • Structural heart disease intervention
  • Echocardiography follow-up
04

Who can participate

Ages eligible
3 Months to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Male and female patients of any age with a hemodynamically or clinically significant muscular ventricular septal defect (mVSD) who are candidates for non-surgical closure with the Occlutech mVSD Occluder in routine clinical practice (predominantly pediatric patients). Eligibility is confirmed based on protocol-defined inclusion/exclusion criteria and baseline clinical assessment, including medical history, demographics, vital signs, ECG and echocardiography; laboratory tests may be performed according to local standard of care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A participant will be eligible for study participation if he/she meets the indication and area of application as laid down in the IFU. The Occlutech mVSD is indicated for percutaneous occlusion of hemodynamically or muscular ventricular septal defects.
  • Any age
  • Male or female.
  • Patients understand the nature of the study and provide their to participation.
  • Patients willing and able to attend the follow-up visits and procedures foreseen by study CIP.

  • Hemodynamically relevant VSD shunt
  • Congestive heart insufficiency
  • Recurrent respiratory infections
  • Failure to thrive.
  • Significant left ventricle (LV) enlargement
  • Significant left atrium (LA) enlargement
  • Other clinical indication

Exclusion criteria

Exclusion Criteria

The device is for participants known to have any of the following:

⦁Active bacterial infections

  • Active infection at the time of implantation
  • Allergy to antiplatelet or anticoagulant therapy
  • Allergy to nickel and/or titanium and/or nickel/titanium-based materials
  • Any type of serious infection 1 month before the procedure
  • The aortic rim of less than 2 mm
  • Demonstrated intracardiac thrombi on echocardiography
  • where is less than 3 years
  • mVSD diameter > 20 mm
  • Perimembranous VSD

Post-MI VSD

  • Recent myocardial infarction or a surgical bypass operation in the last 30 days
  • Sepsis (local or generalized)
  • Septal thickness > 7 mm in the area of the Occluder placement
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • muscular ventricular septal defects

    patients with muscular ventricular septal defects

    Device: Occlutech muscular ventricular septal defect (mVSD) Occluder

Interventions

  • DeviceOcclutech muscular ventricular septal defect (mVSD) Occluder

    Percutaneous, transcatheter (catheter-based) non-surgical closure of a muscular ventricular septal defect (mVSD) using the Occlutech mVSD Occluder. The device is a self-expandable nitinol wire-mesh occluder with two retention discs connected by a flexible waist and incorporates polyester/PET patches to support defect occlusion and tissue ingrowth. Implantation is performed by experienced operators in a specialized cath lab according to the IFU and local routine; device sizing/selection is guided by imaging (e.g., transthoracic echocardiography, angiography, fluoroscopy). The system is deployed using compatible Occlutech delivery accessories (e.g., Occlutech Pistol Pusher and Occlutech Delivery Set \[ODS v1 or ODS III\], as applicable).

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least One Serious Adverse Device Effect (SADE) Within 12 Months After Occlutech mVSD Implantation

    Serious Adverse Device Effects (SADEs) include procedure-related death, stroke, systemic embolism, severe hemolysis, complete heart block requiring pacemaker implantation or device explantation, severe tricuspid regurgitation (TR), severe aortic regurgitation (AR), right ventricular outflow tract obstruction (RVOTO), left ventricular outflow tract obstruction (LVOTO), device embolization, cardiac tamponade, infective endocarditis, or vascular complications requiring open-heart surgery.

    Time frame: Up to 12 months post-procedure

  2. Percentage of Participants With Successful Device Implantation and Trivial or No Residual Ventricular Septal Shunt at 12 Months

    Successful implantation of the Occlutech mVSD Occluder with effective closure defined as reduction of the muscular ventricular septal shunt to trivial or no residual shunt, as assessed by echocardiography.

    Time frame: 12 months post-procedure

Secondary outcomes

  1. Percentage of Participants With at Least One Serious Adverse Device Effect (SADE) Between 1 and 3 Years After Occlutech mVSD Implantation

    Incidence of Serious Adverse Device Effects (SADEs) occurring more than 1 year and up to 3 years after the procedure, including procedure-related death, stroke, systemic embolism, severe hemolysis, complete heart block requiring pacemaker implantation or device explantation, severe TR, severe AR, RVOTO, LVOTO, device embolization, cardiac tamponade, infective endocarditis, or vascular complications requiring open-heart surgery.

    Time frame: 1 year to 3 years post-procedure

  2. Percentage of Participants With Minor Complications, Including Transient Hemolysis and Non-Surgical Vascular Complications, Up to 3 Years

    Minor complications include transient hemolysis, vascular complications not requiring surgery, and other clinically relevant minor complications as assessed by the investigator.

    Time frame: Up to 3 years post-procedure

07

Study locations

1 of 6 sites recruiting
  • Children's Health Ireland
    Dublin, N512, Ireland
    Not yet recruiting
    • Damien Kenny, MD · Contact
    • Claire Josephine Karungi Betz, SC · Contact
  • İzmir Şehir Hastanesi
    Izmir, Bayraklı 35540, Turkey (Türkiye)
    Not yet recruiting
    • Nazmi Narin, MD · Contactnazmi.narin@gmail.com · +90 533 770 64 94
    • Kumru Bademci, SC · Contactkumru.bademci@medex-smo.com · +90 539 895 96 25
    • Nazmi Narin, MD · Principal investigator
    • Kaan Yıldız, Assoc. Prof. Dr., MD · Sub investigator
  • Eskişehir Osmangazi Üniversite Hastanesi
    Eskişehir, Odunpazarı 26040, Turkey (Türkiye)
    Not yet recruiting
  • Dicle Üniversitesi Tıp Fakültesi Hastanesi
    Diyarbakır, Sur, Turkey (Türkiye)
    Not yet recruiting
  • Gaziantep Unıversıty Hospital
    Gaziantep, Şehitkamil 27310, Turkey (Türkiye)
    Recruiting
  • Royal Brompton Hospital
    London, England SW3 6NP, United Kingdom
    Not yet recruiting
    • Prof Alain Fraisse, PI · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jan 2031, 105 months after the start.

Of 185 observational studies under Heart Defects, Congenital, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 105 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2018
First posted
Apr 15, 2022
StartActual
Mar 3, 2022
Primary completionEst.
Jan 1, 2031
CompletionEst.
Jun 1, 2031
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05329350
Lead sponsor
Occlutech International AB
Responsible party
Sponsor
First posted
Apr 15, 2022
Start date
Mar 3, 2022
Primary completion
Jan 1, 2031 (estimated)
Completion
Jun 1, 2031 (estimated)
Last update
Jul 30, 2026

Study contacts

Ahmed Dellaa
Contact
ahmed.dellaa@occlutech.com
+49 151 14139961

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion